Auxilium, Swedish Orphan Biovitrum deal

Auxilium granted Swedish Orphan exclusive rights to develop and commercialize Xiapex collagenase clostridium for Dupuytren's contracture and Peyronie's disease in 71 Eurasian and African countries, including those of the EU. Auxilium is eligible for up to $40 million in sales milestones, plus tiered double-digit royalties. Xiapex is approved in the EU and U.S., where it is known as Xiaflex, to treat Dupuytren's contracture in adult patients with a palpable cord, which affects joints in the hand. The injectable form of collagenase is under review in the U.S. for Peyronie's disease, with a PDUFA date of Sept. 6. Swedish Orphan plans to submit a regulatory application in the EU for the indication in 1H14. Auxilium recorded $20.7 million in 1Q13 revenues for Xiaflex.

Last November, Auxilium and Pfizer Inc. (NYSE:PFE, New York, N.Y.) mutually agreed to terminate a 2008 deal granting the pharma exclusive European and Eurasian commercialization rights to Xiapex (see BioCentury, Nov. 12, 2012). ...